Literature DB >> 18799870

Effective treatment of refractory pulmonary hemorrhage with monoclonal anti-CD20 antibody (rituximab).

Luis Fernando Pinto1, Liliana Candia, Patricia Garcia, Juan Ignacio Marín, Ines Pachón, Luis R Espinoza, Javier Marquez.   

Abstract

We report a 19-year-old female with systemic lupus erythematosus and lupus nephritis who developed pulmonary hemorrhage (PH) refractory to conventional immunosuppressive treatment. She was initially treated with intravenous methylprednisolone and cyclophosphamide pulses. She required mechanical ventilation due to a lack of responsiveness and her disease was considered refractory to conventional treatment. Rituximab was administered and this was followed by clinical improvement in both PH and nephritis. Rituximab may be a useful therapeutic option for the treatment of refractory PH. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799870     DOI: 10.1159/000156965

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  11 in total

1.  Transplantation of umbilical cord mesenchymal stem cells alleviates pneumonitis of MRL/lpr mice.

Authors:  Yanju Zhang; Yunfei Xia; Songshi Ni; Zhifeng Gu; Hua Liu
Journal:  J Thorac Dis       Date:  2014-02       Impact factor: 2.895

Review 2.  B-cell-targeted therapies in systemic lupus erythematosus.

Authors:  Vera Sau-Fong Chan; Helen Hoi-Lun Tsang; Rachel Chun-Yee Tam; Liwei Lu; Chak-Sing Lau
Journal:  Cell Mol Immunol       Date:  2013-01-28       Impact factor: 11.530

Review 3.  Rituximab and lupus--a promising pair?

Authors:  Sara Linder Ekö; Ronald F van Vollenhoven
Journal:  Curr Rheumatol Rep       Date:  2014       Impact factor: 4.592

4.  Pathogenic role of B cells in the development of diffuse alveolar hemorrhage induced by pristane.

Authors:  Tolga T Barker; Pui Y Lee; Kindra M Kelly-Scumpia; Jason S Weinstein; Dina C Nacionales; Yutaro Kumagai; Shizuo Akira; Byron P Croker; Eric S Sobel; Westley H Reeves; Minoru Satoh
Journal:  Lab Invest       Date:  2011-08-01       Impact factor: 5.662

5.  Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience.

Authors:  Yolanda Braun-Moscovici; Yonatan Butbul-Aviel; Ludmila Guralnik; Kochava Toledano; Doron Markovits; Alexander Rozin; Menahem A Nahir; Alexandra Balbir-Gurman
Journal:  Rheumatol Int       Date:  2012-12-14       Impact factor: 3.580

6.  Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival.

Authors:  Nayef M Kazzaz; Patrick Coit; Emily E Lewis; W Joseph McCune; Amr H Sawalha; Jason S Knight
Journal:  Lupus Sci Med       Date:  2015-09-23

7.  Efficacy of Rituximab in a Systemic Lupus Erythematosus Patient Presenting with Diffuse Alveolar Hemorrhage.

Authors:  Gabriela Montes-Rivera; Grissel Ríos; Luis M Vilá
Journal:  Case Rep Rheumatol       Date:  2017-11-15

8.  A fatal case of diffuse alveolar hemorrhage as the initial presentation of systemic lupus erythematosus: A case report and literature review.

Authors:  Abubaker O Abdalla; Jaafar Al-Khafaji; Pydi M Akella; Mohamed Taha
Journal:  Respir Med Case Rep       Date:  2018-04-13

Review 9.  Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective.

Authors:  Pashtoon M Kasi; Hussein A Tawbi; Chester V Oddis; Hrishikesh S Kulkarni
Journal:  Crit Care       Date:  2012-08-31       Impact factor: 9.097

10.  Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndrome.

Authors:  Signe Aakjær; Elisabeth Bendstrup; Per Ivarsen; Line Bille Madsen
Journal:  Respir Med Case Rep       Date:  2017-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.